Home > Neurology > EAN 2022 > Multiple Sclerosis > Updated EAN-ECTRIMS guideline on pharmacological MS treatment

Updated EAN-ECTRIMS guideline on pharmacological MS treatment

Presented By
Prof. Maria Pia Amato, University of Florence, Italy
EAN 2022
The new EAN-ECTRIMS guideline includes the advice to treat young secondary progressive multiple sclerosis (SPMS) patients with siponimod or anti-CD20 monoclonal antibodies, regardless of the lack of evidence on efficacy, safety, and tolerability. Additionally, starting earlier with higher-efficacy disease modifying drugs (DMDs) is suggested when treating patients with unfavourable prognosis. If a high-efficacy DMD treatment is terminated, a different high-efficacy DMD should be started. The radiologically isolated syndrome (RIS) is not however included in the guideline, due to a lack of evidence. The new EAN-ECTRIMS guideline “Update on the pharmacological treatment of people with multiple sclerosis” was presented at the EAN 2022 meeting [1]. Prof. Maria Pia Amato (University of Florence, Italy) summarised the main questions the guideline addresses. The 5 core topics of the guideline include: Efficacy of DMDs. Early t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on